PDCD1 and cancer: In the recent years, cancer immunotherapy made a significant breakthrough due to the development of adoptive T cell therapies and the use of monoclonal antibodies blocking the CTLA-4 and programmed cell death 1 (PD1) immune checkpoints [1–7].